Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study.
Lucas F Borkel, Jaime Rojas-Hernández, Luis Alberto Henríquez-Hernández, Ángelo Santana Del Pino, Domingo J Quintana-Hernández
Expert Review of Clinical Pharmacology 2024 DOI: 10.1080/17512433.2023.2295997 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Longitudinal Peer reviewed |
|---|---|
| Sample size | 1,022 |
| Population | Spanish-speaking population |
| Keywords | Spanish-speaking population Drug use Mental health Psychopathology Psychedelics hallucinogens Entheogens Psychoactive substances Mental wellness Psychiatric health Context Mindset |
| Citations | 40 |
| Key findings | Growth motivations, natural settings, and presence of significant others predict less psychopathology and greater wellbeing, while problematic motivations predict greater psychopathology and lower wellbeing. |
Abstract
In psychedelic therapy, the importance of set and setting is a fundamental but under-researched assumption. The aim of this study is to correlate variables of set (psychedelic use motivation) and setting (psychedelic use location and type of companion) with psychopathology, wellbeing and personality variables. A sample of 1022 participants of the Spanish-speaking population was collected through an online survey. A novel instrument, the Psychedelic Use Scale (PUS), was developed to measure substance use variables of LSD, mescaline, psilocybin, DMT, 5-Meo-DMT, ketamine, Salvia divinorum, ibogaine and MDMA. Various personality, well-being and psychopathology instruments were implemented to measure outcome variables. Growth motivations, natural settings and presence of significant others predicted less psychopathology, greater wellbeing and meaningfulness of psychedelic experiences, whereas problematic motivations predicted greater psychopathology, lower wellbeing and did not predict meaningfulness of psychedelic experiences. Based on these results, we suggest experimental hypotheses for future clinical trials and longitudinal studies with potential clinical implications.
Citations in the library
Cited by 42
- Wolves Among Sheep: Sexual Violations in Psychedelic-Assisted Therapy. The American Journal of Bioethics January 13, 2025
- Females in Psychedelic Research: A Perspective for Advancing Research and Practice. ACS Pharmacology & Translational Science July 11, 2025
- Regulatory Challenges of Integrating Psychedelics into Mental Health Sector Psychoactives April 22, 2025
- Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science Translational Behavioral Medicine October 17, 2024
- Naturalistic psychedelic experiences and gender-based self-acceptance in transgender and gender-expansive people International Journal of Transgender Health March 19, 2025
and 37 more in the library
Cites 51
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
- Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness Journal of Psychopharmacology September 28, 2011
- Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Frontiers in Pharmacology January 17, 2018
- Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder The Journal of Clinical Psychiatry November 15, 2006
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder JAMA Psychiatry August 24, 2022
and 46 more in the library